Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Merck & Co., Inc. : Lawsuit Claims Merck Overstated Mumps Vaccine Effectiveness

share with twitter share with LinkedIn share with facebook
share via e-mail
06/22/2012 | 07:32pm CEST
   By Jon Kamp 

Two former Merck & Co. Inc. (MRK) employees have sued the company in federal court alleging Merck overstated the effectiveness of a mumps vaccine for which the U.S. government paid hundreds of millions of dollars.

Merck--which stressed that none of these allegations relate to the safety of its product--said the lawsuit is "completely without merit", and that it plans to "vigorously defend itself." The Whitehouse Station, N.J., drug maker also noted that the U.S. Department of Justice has thus far declined to participate in the case after its own two-year probe.

Mumps is a contagious disease that causes symptoms like fever, headache and swollen salivary glands. It was a common illness for kids and young adults before childhood vaccinations became common decades ago, according to the Centers for Disease Control and Prevention, although there were outbreaks in 2006 and 2009. The agency says vaccines are the best way to prevent mumps.

Merck introduced the first vaccine 45 years ago, and since the 1970s it's been part of a combination product that also immunizes children against rubella and measles. According to the lawsuit--filed by former Merck virologists Stephen Krahling and Joan Wlochowski--the company allegedly defrauded the U.S. for more than a decade by hiding the fact the vaccine had become less effective.

As a result, the former employees say the government has long paid for a product that doesn't live up to Merck's claims. The lawsuit seeks a judgment against Merck equal to three times the damages suffered by the U.S., plus the maximum allowable award for the former employees under federal whistleblower laws.

The suit was first filed in 2010 in the U.S. District Court for the Eastern District of Pennsylvania. It was unsealed Thursday after the government declined to get involved in the case.

Merck confirmed Krahling and Wlochowski were former employees, but it said they haven't worked at the company for a decade.

"It's important to understand that none of the allegations in the complaint relate to the safety of M-M-R II"--the vaccine in question--"and we remain confident that M-M-R II helps protect against measles, mumps and rubella as described in the labeling for the vaccine," Merck said in a statement.

"M-M-R II continues to be recommended for routine administration to children by public health authorities around the world, including the U.S. Centers for Disease Control and Prevention and the U.S. Food and Drug Administration," the company said.

Merck doesn't specifically break out sales for the vaccine, but the company reported combined U.S. sales of $1.1 billion last year for that product and two other childhood vaccines. Merck shares recently traded up 1.9% to $40.19 and have risen 6.6% this year.

Write to Jon Kamp at [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK AND COMPANY
07/14MERCK AND : Mercks sBLA for Keytruda to treat patients with advanced hepatocellu..
07/13MERCK AND : FDA Grants Priority Review to Merck's Supplemental Biologics License..
07/12MERCK AND : Bristol-Myers Squibb`s Opdivo-Yervoy combo wins right to challenge M..
07/11MERCK AND : Keytruda Gets FDA Priority Review in Liver Cancer
07/11MERCK AND : FDA Grants Priority Review to Merck’s Supplemental Biologics L..
07/11ALLERGAN : Forbion raises EUR 270M, surpassing target for fourth fund
07/06HITTING CANCER EARLY : AstraZeneca's bid to outmaneuver rivals
07/06MERCK AND : & Co., Inc. - FDA Grants Priority Review to 's Supplemental Biologic..
07/06MERCK AND : AstraZeneca - Lynparza approved in Japan for BRCA-mutated metastatic..
07/06MERCK AND : to Present New Data from Studies of Investigational HIV Therapy Dora..
More news
News from SeekingAlpha
07/18ARBUTUS BIOPHARMA : Long-Term Growth Prospect Flying Too Close To The Sun 
07/18FDA committed to easing approval path for biosimilars 
07/18FDA OKs J&J's single tablet darunavir-based regimen for HIV-1 
07/17Gilead's HIV Franchise Under Assault As It Stares Down Paradigm-Changing Drug 
07/16CVS responds to Trump Administration's request for info on now to lower drug .. 
Financials ($)
Sales 2018 42 031 M
EBIT 2018 13 523 M
Net income 2018 7 169 M
Debt 2018 15 697 M
Yield 2018 3,10%
P/E ratio 2018 24,16
P/E ratio 2019 16,70
EV / Sales 2018 4,38x
EV / Sales 2019 4,17x
Capitalization 168 B
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 69,4 $
Spread / Average Target 10%
EPS Revisions
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY11.85%168 225
JOHNSON & JOHNSON-8.53%346 292
PFIZER3.98%220 236
ROCHE HOLDING LTD.-5.88%200 995
NOVARTIS-5.10%200 139
AMGEN10.87%128 318